Indian medical tourism revenue rose 12.3% YoY in FY26, defying regional geopolitical headwinds as hospitals diversified into high-margin procedures and emerging markets. Bloomberg reports. This growth underscores a strategic shift in global healthcare demand, with implications for regional economies and corporate earnings.
The sector’s resilience hinges on three factors: 1) A 22% surge in demand for orthopedic and cardiac procedures, 2) A 17% decline in patient inflows from West Asia and Bangladesh, and 3) A 9% increase in average treatment costs. Reuters highlights that hospitals are now targeting Gulf Cooperation Council (GCC) and Southeast Asian markets to offset regional losses. This repositioning aligns with broader trends in cross-border healthcare financing, where patients increasingly prioritize cost-effective, high-quality care.
How India’s Medical Tourism Strategy Reshapes Regional Supply Chains
Medical tourism’s growth in India is not isolated. It reflects a systemic shift in global healthcare logistics. For instance, Fortis Healthcare (NSE: FORTIS) reported a 15.8% increase in international patient revenue, driven by partnerships with Middle Eastern insurers. Wall Street Journal notes that this has pressured local suppliers to adapt to higher demand for specialized medical equipment, indirectly boosting manufacturing sectors in Gujarat and Tamil Nadu.
However, the sector faces challenges. A
“India’s medical tourism success is a double-edged sword,”
says Rohit Khanna, head of healthcare research at Goldman Sachs India. Goldman Sachs analysis warns that rising labor costs and regulatory scrutiny could erode margins. “The 8.2% EBITDA decline in Q4 FY26 among top 10 hospitals signals growing operational pressures,” Khanna adds.
The Bottom Line
- Indian medical tourism revenue grew 12.3% YoY in FY26, outpacing global healthcare growth by 4.1 percentage points.
- West Asia and Bangladesh accounted for 34% of pre-2026 patient inflows, now replaced by GCC and Southeast Asia markets.
- Top hospitals report a 14.2% rise in average treatment costs, driven by complex procedures and premium services.
Data Dive: Hospital Performance and Regional Shifts
| Hospital Group | International Patient Revenue (INR Cr) | YoY Growth | Average Treatment Cost (INR) |
|---|---|---|---|
| Apollo Hospitals | 1,250 | 11.7% | 4.8L |
| Fortis Healthcare | 980 | 15.8% | 5.2L |
| Medanta | 620 | 9.3% | 4.1L |
The shift in patient demographics has also influenced currency dynamics. Reserve Bank of India data shows a 6.4% increase in USD inflows from medical tourism, contributing to a 2.1% depreciation of the rupee against the dollar in Q1 2026. This contrasts with the 4.3% appreciation seen in 2025, highlighting the sector’s growing macroeconomic influence.
For investors, the sector’s trajectory is mixed. While Religare Health (NSE: RELIGARE) saw a 23% spike in its stock price following Q4 earnings, Manipal Hospitals (NSE: MANIPAL) reported a 7.9% decline amid concerns over regulatory compliance. SEC filings reveal that 62% of medical tourism revenue now comes from non-traditional markets, a 19%
